BioWorld

May 1, 2003

View Archived Issues

Genzyme, BioMarin Receive FDA's Aldurazyme Approval

Genzyme General and its partner, BioMarin Pharmaceutical Inc., received FDA approval for Aldurazyme, an enzyme replacement therapy for the treatment of a rare degenerative disease, mucopolysaccharidosis-1. (BioWorld Today) Read More

Rigel Secures Agreements For $46 Million Private Placement

Read More

Bug's Chromosomal 5.2 Million Bases, 5,508 Genes In Plasmids Define Pathogenicity, Virulence

Read More

Post-Genomics Survival Demands Speed, Novelty, Broadened Scope

Read More

The Changing Face Of ImClone: Another Waksal Stepping Down

Read More

Other News To Note

Read More